PUMA BIOTECHNOLOGY, INC. (PBYI) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 0.00 USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 0.00 USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | 93.90M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 192.74M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $0.00 | $0.00 | (m) | $93.90M | $192.74M | (m) |
| 2026-03-31 | (m) | (m) | $11.28M | $0.00 | (m) | $101.55M | $192.70M | (m) |
| 2025-12-31 | (m) | (m) | $22.52M | $0.00 | (m) | $97.53M | $216.30M | (m) |
| 2025-09-30 | (m) | (m) | $33.72M | $0.00 | (m) | $94.39M | $202.86M | (m) |
| 2025-06-30 | (m) | (m) | $34.00M | $10.87M | (m) | $96.02M | $194.92M | (m) |
| 2025-03-31 | (m) | (m) | $45.33M | $10.65M | (m) | $93.17M | $196.18M | (m) |
| 2024-12-31 | (m) | (m) | $45.33M | $21.72M | (m) | $100.97M | $213.33M | (m) |
| 2024-09-30 | (m) | (m) | $45.33M | $32.75M | (m) | $96.72M | $220.72M | (m) |
| 2024-06-30 | (m) | (m) | $45.33M | $43.73M | (m) | $96.83M | $205.00M | (m) |
| 2024-03-31 | (m) | (m) | $45.33M | $54.69M | (m) | $107.16M | $214.15M | (m) |
| 2023-12-31 | (m) | (m) | $34.00M | $65.66M | (m) | $95.94M | $230.53M | (m) |
| 2023-09-30 | (m) | (m) | $22.66M | $76.63M | (m) | $85.03M | $203.60M | (m) |
| 2023-06-30 | (m) | (m) | $11.33M | $87.62M | (m) | $74.44M | $200.49M | (m) |
| 2023-03-31 | (m) | (m) | (m) | $98.62M | (m) | $71.22M | $196.26M | (m) |
| 2022-12-31 | (m) | (m) | (m) | $98.31M | (m) | $81.07M | $222.06M | (m) |
| 2022-09-30 | (m) | (m) | (m) | $97.99M | (m) | $77.96M | $198.77M | (m) |
| 2022-06-30 | (m) | (m) | (m) | $97.68M | (m) | $60.75M | $193.65M | (m) |
| 2022-03-31 | (m) | (m) | (m) | $97.38M | (m) | $73.91M | $200.69M | (m) |
| 2021-12-31 | (m) | (m) | $0.00 | $97.09M | (m) | $82.11M | $226.59M | (m) |
| 2021-09-30 | (m) | (m) | $0.00 | $96.80M | (m) | $87.54M | $226.29M | (m) |
| 2021-06-30 | (m) | (m) | $31.43M | $68.71M | (m) | $108.97M | $260.00M | (m) |
| 2021-03-31 | (m) | (m) | $22.86M | $76.35M | (m) | $109.05M | $258.66M | (m) |
| 2020-12-31 | (m) | (m) | $14.29M | $84.03M | (m) | $93.39M | $244.22M | (m) |
| 2020-09-30 | (m) | (m) | $5.71M | $91.71M | (m) | $109.02M | $261.69M | (m) |
| 2019-12-31 | (m) | (m) | (m) | $94.96M | (m) | $111.64M | $234.91M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |